Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.33 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.33 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.33 |
| ▸ | FABP3 | P05413 | 2/20 | 0.33 |
| ▸ | FABP4 | P15090 | 2/20 | 0.33 |
| ▸ | FABP5 | Q01469 | 1/20 | 0.32 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.31 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.31 |
| ▸ | PKM | P14618 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13035782 | 0.85 | TDP1 (0.47) | TDP1PKM | |
| SCHEMBL13036606 | 0.83 | TDP1 (0.40) | TDP1ALDH1A1CYP11B1CYP11B2PKM | |
| SCHEMBL69284 | 0.75 | NOTUM (0.37) | TDP1GABRA1GABRB2CYP11B1CYP11B2 | |
| SCHEMBL69983 | 0.73 | TDP1 (0.51) | TDP1ALDH1A1CYP11B1CYP11B2PKM | |
| SCHEMBL26700013 | 0.72 | TNKS (0.38) | ALDH1A1GABRA1GABRB2FABP3FABP4 | |
| SCHEMBL26700024 | 0.71 | GABRA1 (0.36) | ALDH1A1GABRA1GABRB2FABP3FABP4 | |
| SCHEMBL26700032 | 0.71 | TNKS (0.34) | ALDH1A1GABRA1GABRB2FABP3FABP4 | |
| SCHEMBL25722874 | 0.71 | TDP1 (0.52) | TDP1CYP11B1CYP11B2PKM | |
| SCHEMBL15159089 | 0.71 | TDP1 (0.49) | TDP1CYP11B1CYP11B2PKM | |
| SCHEMBL13054420 | 0.70 | GABRA1 (0.38) | ALDH1A1GABRA1GABRB2FABP3FABP4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230348452-A1 | COMPOUNDS AND USES THEREOF | FOGHORN THERAPEUTICS INC. | 2023-11-02 | — | — | US | disclosed |
| US-20230348452-A1 | COMPOUNDS AND USES THEREOF | FOGHORN THERAPEUTICS INC. | 2023-11-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230348452-A1 | COMPOUNDS AND USES THEREOF | VHL, CLN6, BRCA1 | TDP1 465/4885ALDH1A1 2600/4885GABRA1 444/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.